GlassScriptPhysician profile
Beth M Wendt
NPI 1972505501
$1,108.89
in general payments reported to CMS, 2019-2025
19 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $148 · 2021: $264 · 2022: $67.29 · 2023: $140 · 2024: $134 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $365.53 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $137.09 | 2020-2023 | Xarelto |
| Amgen INC. | $69.00 | 2019-2021 | |
| Lilly USA, LLC | $65.70 | 2025 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $64.58 | 2019 | |
| Getinge USA Sales, LLC | $58.26 | 2025 | Flixene |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.61 | 2021-2023 | Xifaxan |
| Cook Medical LLC | $48.02 | 2024-2025 | Lunderquist, Zenith, Zenith Spiral-Z |
| Teva Pharmaceuticals USA, INC. | $42.13 | 2019-2020 | |
| Polynovo North America LLC | $26.33 | 2024 | Novosorb Btm |
| Abbvie INC. | $25.88 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $25.58 | 2021 | |
| Integra Lifesciences Corporation | $24.40 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Organogenesis INC. | $24.03 | 2025 | Puraply Wound Matrix |
| Portola Pharmaceuticals, LLC | $18.61 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $18.49 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.17 | 2022 | |
| Glaxosmithkline, LLC. | $14.30 | 2023 | Trelegy Ellipta |
| Pfizer INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Wendt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.